Back to Search Start Over

Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center.

Authors :
Guerra, Renata Leborato
Dos Reis, Neilane Bertoni
Corrêa, Flávia De Miranda
Fernandes, Myrian Machado
Ribeiro Alves Fernandes, Ricardo
Cancela, Marianna De Camargo
Araújo, Rodrigo Moura De
Crocamo, Susanne
Santos, Marisa
De Almeida, Liz Maria
Source :
Expert Review of Pharmacoeconomics & Outcomes Research; Apr2020, Vol. 20 Issue 2, p185-191, 7p
Publication Year :
2020

Abstract

Objectives: To evaluate health-related-quality-of-life and derive health-state-utility (HSU) from breast cancer patients, before and after routine therapy at a Brazilian reference public cancer center.Methods: In a prospective cohort study, a consecutive sample of outpatients newly diagnosed with breast cancer was submitted to two interviews (baseline, 6-month) to complete EQ-5D-3L/VAS and EORTC-QLQ-C30/BR23 questionnaires. Demographic and clinical information was reviewed from medical records.Results: For 196 patients, EQ-5D domains of pain/discomfort and anxiety/depression were mainly affected, but partially improved overtime, while mobility/usual activities/self-care worsened after therapy. EORTC-QLQ-C30/BR23 scales mostly affected were emotional functioning, insomnia, pain, sexual enjoyment and future self-health perspective at baseline, while financial difficulties, insomnia, fatigue and therapy side-effects at follow-up. Overtime mean scores were 71.4 (95%CI68.5-74.4) and 76.1 (95%CI73.3-78.8) for EQ-5D-VAS, and 0.712 (95%CI0.686-0.737) and 0.732 (95%CI0.707-0.757) for HSU. HSU was 0.689 (95%CI0.648-0.730) in stages III-IV, and 0.692 (95%CI0.652-0.731) under two/three chemotherapy regimens.Conclusion: In a context of impairments in emotional functioning, sexual enjoyment, symptoms burden, and poor future self-health perspective, breast cancer produced a mean HSU of 0.712. After routine care, there was a small improvement in quality of life, with lower HSU particularly in advanced disease and multiple chemotherapy regimens. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14737167
Volume :
20
Issue :
2
Database :
Complementary Index
Journal :
Expert Review of Pharmacoeconomics & Outcomes Research
Publication Type :
Academic Journal
Accession number :
143114351
Full Text :
https://doi.org/10.1080/14737167.2019.1621752